Biosimilars

The medtech firm reports a 19% revenue surge and a return to profitability, validating its new pure-play strategy focused on the surgical market.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

Biotech firm Ocubio adds commercial titan Jim Mazzo and clinical pioneer Dr. Eric Donnenfeld, signaling a major play to disrupt the ocular health market.

Henlius and Organon's POHERDY gains EC approval, set to expand access and lower costs for a critical breast cancer therapy across the European Union.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

The Health Research Foundation opens nominations for its equity award, spotlighting researchers who are closing critical health gaps for diverse communities.

EXALTA Group's new ISO 17025 accreditation for its in-house lab aims to slash development time, reflecting a broader industry push for integrated partners.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

FDA approves the first generic of a vital nutrition drug, granting Apotex a 180-day exclusive edge and signaling major cost savings for healthcare.

An unlikely partnership between a rural church and a treatment center is bringing a mobile clinic to Western North Carolina, offering hope on the front lines.

New Medicare billing codes for the biosimilar Tyenne are now in effect, simplifying reimbursement and aiming to improve access for severe COVID-19 patients.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

President Trump's 100% tariff on imported drugs aims to secure the US supply chain, but the policy's success may hinge on unproven and unverified players.

A new tool reveals how a federal drug program may be inflating healthcare costs for businesses, intensifying the debate over transparency and reform.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

Parnell’s nixiFLOR, the first generic of Resflor Gold®, offers a cost-effective new weapon for ranchers battling Bovine Respiratory Disease.

With its lead drug for a rare pediatric liver disease entering late-stage trials, NorthSea Therapeutics adds a veteran drug developer to its board.

Landmark study results show a new drug-coated balloon significantly improves outcomes for Peripheral Artery Disease, heralding a major shift in treatment.